Investors are overlooking healthcare stocks and should consider these top picks, says JPMorgan

Investors have been overlooking healthcare stocks, according to JPMorgan, which has identified several top picks in the sector. Eli Lilly, AbbVie, and Danaher Corporation are among the bank's recommended stocks. This comes as a surprise, given the sector's historical stability and growth potential. Healthcare stocks have often been considered defensive plays, as demand for medical treatments and pharmaceuticals remains relatively inelastic.

The recommendation to consider healthcare stocks now may be driven by factors such as attractive valuations, potential for long-term growth, and the likelihood of increased M&A activity in the sector. JPMorgan's top picks likely reflect a combination of these factors, as well as the companies' strong fundamentals and competitive positions. For fund managers, adding healthcare stocks to their portfolios could provide a diversification benefit and help mitigate risk.

To watch next: performance of JPMorgan's recommended stocks, Eli Lilly, AbbVie, and Danaher Corporation, in the coming quarters. Also, keep an eye on broader market trends and sector developments, such as regulatory changes, drug pricing pressures, and emerging technologies. Additionally, monitor if other brokerages and analysts start to recommend similar healthcare stocks, which could indicate a growing consensus on the sector's prospects.

Originally reported by marketwatch.com. FundNews adds analysis for finance & markets readers.